Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Viread

Viread 245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 131–132

HOS-110776 · Präparat HOS-093385

131  Medicinal product by Effects on drug levels Recommendation therapeutic areas Mean percent change in AUC, Cmax, concerning (dose in mg) Cmin co-administration with 245 mg tenofovir disoproxil Entecavir AUC: ↔ No clinically significant Cmax: ↔ pharmacokinetic interactions when tenofovir disoproxil was co-administered with entecavir. Hepatitis C virus antiviral agents Ledipasvir/Sofosbuvir Ledipasvir: Increased plasma (90 mg/400 mg q.d.) + AUC: ↑ 96% concentrations of tenofovir Atazanavir/Ritonavir Cmax: ↑ 68% resulting from (300 mg q.d./100 mg q.d.) + Cmin: ↑ 118% co-administration of tenofovir Emtricitabine/Tenofovir disoproxil, disoproxil Sofosbuvir: ledipasvir/sofosbuvir and (200 mg/245 mg q.d.)1 AUC: ↔ atazanavir/ritonavir may Cmax: ↔ increase adverse reactions related to tenofovir disoproxil, GS-3310072: including renal disorders. The AUC: ↔ safety of tenofovir disoproxil Cmax: ↔ when used with Cmin: ↑ 42% ledipasvir/sofosbuvir and a pharmacokinetic enhancer Atazanavir: (e.g. ritonavir or cobicistat) AUC: ↔ has not been established. Cmax: ↔ Cmin: ↑ 63% The combination should be used with caution with Ritonavir: frequent renal monitoring, if AUC: ↔ other alternatives are not Cmax: ↔ available (see section 4.4). Cmin: ↑ 45%

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) atazanavir (HOS-086180) sofosbuvir (HOS-108928) ledipasvir (HOS-110493) cobicistat (HOS-088111) entecavir (HOS-088124) hepatitis C virus (HOS-108813) ritonavir (HOS-084521) emtricitabine (HOS-085840)